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Introduction
In humans, the proto-oncogene HER-2/neu (neu) is overexpressed in 35-40% of all breast cancers (1) . Although patients with neu expressing tumors develop antibody and T cell responses to this antigen, these responses are weak and unable to hinder tumor growth. This suggests that T cell tolerance is a significant barrier to immune based treatments that target neu and most likely other antigens expressed by breast cancers. HER-2/neu (neu-N) transgenic mice express the wild type rat neu cDNA under control of the MMTV promoter (2) . Female mice spontaneously develop focal mammary tumors which overexpress the transgene in a stochastic manner starting approximately at 4 months of age. Since neu is an endogenously expressed antigen, it is likely that neu-specific immune tolerance exists in the neu-N mice. Three findings strongly support the existence of neu-specific tolerance in these mice. First, subcutaneous injection of 100-fold less transplantable neu-expressing mammary tumors is required for tumor growth in the neu-N mice when compared with the parental FVB/N mice. Second, neu-specific vaccines designed to prevent tumor development provide long-term prevention of neu-expressing tumors in the FVB/N mice but only delay slightly tumor growth in the neu-N mice. Third, neuspecific CD8÷ T cells (CTL) derived from FVB/N mice can lyse neu-expressing mammary tumors much more effectively than T cells derived from neu-N mice. (3) Based on these findings, the neu-N transgenic mouse model of mammary tumors provides a clinically relevant model for developing vaccines that overcome tumor tolerance. The overall aim of this work is to determine the mechanisms by which immune tolerance of CTL inhibits effective immunization in the neu-N transgenic mice and discover ways to circumvent them to increase the effectiveness of cancer vaccines.
Body

Identification of specific HER-2/neu MHC class Ipeptide epitopes
To study the mechanisms of CD8÷ T cell tolerance to neu in the neu-N mice, we first identified an immunodominant, MHC class I restricted T cell epitope from the neu protein. This research is described in detail in the attached manuscript in the appendix from the Journal of Immunology (J. Immunology, 2003, 170: 4273-4280) . Briefly, neu-specific T cell lines were generated from vaccinated FVB/N mice by repeated in vitro stimulation with neu-expressing target cells. T cell lines, determined to be neu-specific by in vitro lysis assays, were then screened for activity against 9 cell lines, each expressing a fragment of the whole neu protein. Several T cell lines were activated by fragment 4 of neu. The T cell lines were then screened for activity against overlapping 1 0-mer peptides spanning the sequence of fragment 4. Each line reacted to the 10-mer comprising amino acids 420-429 (PDSLRDLSVF) of neu. We also determined that RNEU 420 -429 is naturally processed and presented by tumor cells and is the optimal epitope in comparison to 8-and 9-mer derivatives.
We also generated T cell lines from neu-N mice given a neu targeted vaccine. Although multiple neu-specific lines were grown, only one recognized RNEU 420 -429 . Significant efforts have been made to identify other neu T cell epitopes recognized by the other T cell lines. The method described to identify the RNEU 420 -429 epitope was unsuccessful. None of the neu-Nderived .T cell lines recognized any of the 9 neu fragments. A combinatorial peptide library was also screened with the neu-N derived T cells employing a method others have used to discover T cell eptitopes (4) . Again, after several attempts, no T cell epitopes could be determined from the data. We are continuing efforts to discover other neu T cell epitopes by utilizing bone-marrow derived dendritic cells that are infected with recombinant Listeria that express fragments of neu. We are also undertaking a large peptide synthesis approach where we are synthesizing overlapping 10-mers across the whole neu sequence.
Upon further study, we have shown by ex vivo analysis of T cell activation that all FVB/N mice given a neu-targetted vaccine generate RNEU 420 . 429 -specific T cells, whereas RNEU 42 0a 29 -specific T cells are rarely observed in neu-N mice given the same vaccine.
Hypothesizing that functional T cell tolerance to RNEU 4 2 0 . 4 2 9 in the neu-N mice could be one of the main mechanisms preventing effective anti-tumor immunity, we invested a significant amount of time and resources in developing reagents to study RNEU 420 . 429 -specific T cell responses.
Construction of H2-Dq RNEU 42 0-429 dimer and tetramer
To study the T cell Receptor (TCR)/MHC class I/peptide interaction of RNEU 420 -429 -specific T cells, a MHC class I dimer loaded with RNEU 42 04 29 was made according to established protocols (5) . Specific staining of RNEU 420 _ 429 -specific T cells was observed (data not shown), however the dimer reagent did not provide the sensitivity to detect T cell populations ex vivo nor could be used to estimate T cell receptor avidity. MHC tetramers have been shown to provide much cleaner staining of T cell lines and can detect T cells specific to the bound peptide epitope directly ex vivo. Tetramer has also been used to study the avidity of TCR/MHC/peptide interactions. Because of these issues, we chose to not use the MHC dimer, but instead we made a 
Analysis of T cellpeptide epitopes for MHC class I binding affinity
Affinity for peptide epitopes for its cognate MHC class I molecule impacts how it is presented by antigen presenting cells (APC) and how well the TCR interacts with the APC. Several methods are available to test binding affinity. Surface plasmon resonance gives very precise measurements of binding affinities, yet is very labor intensive. As our intent is to simply determine which epitopes would be most effectively presented to T cells, we decided to use assays that give a more functional readout of peptide binding as opposed to a precise binding constant. We first determined the optimal peptide length of RNEU 42 0 _ 429 for binding to MHC I. A T2 cell binding assay was performed on the peptides of interest. T2 cells lack the TAP transporter and as a result cannot present endogenous peptides on MHC I. The lack of peptide causes the MIC to be unstable and be quickly internalized and degraded. Peptide binding can be assayed by incubating the T2 cells in serum free media containing the peptide of interest and then staining for MHC class I. Cells are then fixed and analyzed by flow cytometry. The level of MHC I expression is measured and will be highest on cells incubated with the peptide that binds to MHC I the best. We transfected T2 cells with murine H2-Dq to assay the binding of neu peptide epitopes. 8-mer and 9-mer variants covering RNEU 4 2 0.4 2 9 were assayed. Figure 2 plots the mean fluorescence intensity of MHC I staining after the T2-Dq cells were incubated with different peptides. The 1 0-mer RNEU 420 -429 was determined to be the optimal length for binding to H2-D . It was also noted that if the terminal phenylalanine at position 10 was removed no binding was observed, indicating its role as perhaps a crucial anchor residue for peptides in 112-Dq. To further investigate the role of each residue for MHC binding, alanine substitutions at each position were made and binding to T2-Dq cells was measured ( Figure 3 ). When alanine was substituted at positions 4 and 10 of RNEU 420 -429 , binding to T2-Dq cells was abolished. These results indicate that the leucine at position 4 and the phenylalanine at position 10 are critical for binding to H2-Dq and serve as anchor residues for binding in the peptide binding groove of 112-Dq. The position of the anchor residues for H2-Dq has not previously been reported. 
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The second assay used to study peptide binding is an in vitro lysis assay employing T cells specific to the peptide epitopes being tested. Target cells, in our case T2-Dq cells, are pulsed with serial dilutions of each peptide and labeled with 'Cr. The targets are then incubated with the T cells and, after 4 hours, lysis of the targets is measured by determining the level of 51 Cr in each sample. Peptides with higher binding affinities will cause increased lysis at lower concentrations. The results of these assays are included in the next section as we used the assay to determine variants of RNEU 42 0-4 29 that bind to H2-Dq with higher affinity.
Create amino acid substitutions in RNEU 420 -4 29 to generate a more immunogenic peptide
Other systems have shown that T cell epitopes can be rendered more immunogenic by varying the peptide to bind more tightly to MHC I (6). As tolerance to RNEU 420 -429 in neu-N mice appears to contribute to the lack of effective antitumor immunity, we searched for altered peptide analogues of the immunodominant neu peptide that had enhanced immunogenicity in our system. Altered forms of RNEU 42 0-4 29 were created by substituting alanine at each of the 10 positions. This type of approach has been successful in identifying heteroclitic T cell peptides in both rodent and human settings (6). In the majority of cases, substitutions did not enhance recognition. However, when alanine was substituted for glutamate at position 2, this peptide (designated RNEU 420 . 429 A2) demonstrated markedly improved recognition by a FVB/N-derived T cell clone in the lysis assay described above as compared with wild-type peptide (Figure 4 ). To determine if this heteroclitic peptide can immunize mice against mammary tumor expressing the natural RNEU 4 20 -4 2 9 epitope, both wild-type RNEU 4 2 0 -42 9 and the heteroclitic variant RNEU 420 -429 A2 were used to vaccinate mice. Dendritic cells derived from FVB/N mice were pulsed in vitro with either of these peptides (or with an irrelevant peptide) and then injected subcutaneously into FVB/N and neu-N mice followed by a subcutaneous challenge with the neuexpressing mammary tumor line NT2. As shown in . 25 * 25-
days post tumor challenge days post tumor challenge
Determine avidity of RNEU 42 o-429 -specific T cells for MHC/peptide complex
Several reports looking at TCR avidity to self antigens found that mechanisms of tolerance delete the CD8÷ T cells expressing the highest avidity TCR to self antigens, leaving only low avidity T cells that can be activated against a self antigen (7). If this is the case, tumor vaccines might only activate low avidity T cells specific for a tumor antigen that are poorly lytic and ineffective at eradicating tumor. Attempts to improve tumor vaccines could then focus on increasing the activity or quantity of these low avidity T cells. One such approach is vaccinating with a heteroclitic epitope as discussed above.
Another approach to improving vaccine efficacy that our lab has pioneered is combining vaccine with immunomodulatory doses of chemotherapy. Combining the granulocyte macrophage colony stimulating factor (GM-CSF)-secreting vaccine with cyclophosphamide (Cy) given I day before vaccine (100 mg/kg) and doxorubicin (Dox) given 7 days after vaccine (5 mg/kg) improves long term tumor free survival in neu-N mice to 20-30% as opposed to 0% long term survival in groups given vaccine alone or mock vaccine plus chemotherapy (8) . Upon analysis of the T cell response generated in the vaccine + chemotherapy treated neu-N mice, RNEU 42 0_ 429 -specific T cells were only found in mice that remained tumor free and never in mice where tumors grew out (data not shown). We wanted to test whether or not the T cells activated in the vaccine + chemotherapy treated mice were low avidity T cells that had been rendered more active by the chemotherapy or if the chemotherapy somehow allowed high avidity T cells for Three RNEU 420 o 429 -specific T cell lines were analyzed for TCR avidity using the H2-DqRNEU420.429 tetramer described above: 1. T cell line derived from vaccinated FVB/N mice 2. T cell line from neu-N mice given vaccine alone and 3. T cell line from neu-N mice that had remained tumor free following vaccine + chemotherapy. Each T cell line was shown to be uniformly reactive to RNEU 420 -429 by intracellular cytokine staining following peptide stimulation (data not shown). The TCR and CD8 expression level of each line was also determined and shown to be equivalent (data not shown). Next each line was stained with increasing dilutions of tetramer ( Figure 6 ). The cells were fixed and intensity of tetramer staining was analyzed by flow cytometry. If the T cell lines express equivalent levels of TCR, then tetramer staining intensity at each dilution will directly correlate with the strength of interaction between the TCR and the peptide/MHC complex. High avidity T cell lines will maintain higher tetramer staining levels at low tetramer concentrations, whereas a low avidity T cell line will stain very poorly at low tetramer concentrations. The FVB/N line ( Figure 6a ) and the neu-N + chemotherapy line (Figure 6c ) still showed a shift in tetramer staining at a 1:500 dilution, whereas the neu-N line (Figure 6b) showed no shift after the 1:5 dilution. From this data, it appears that the T cell line from the neu-N mice given chemotherapy is a high avidity T cell, despite being specific to an endogenous self antigen. 1500 tetramer dilution S.... unstained As this data contradicts findings in other models where only low avidity T cells to self antigens can be activated, we sought additional data to confirm these results. A "tetramer falloff" assay was designed to determine the binding affinity of the TCR/MHC/peptide complex. Cells were first shown to have equivalent TCR expression levels. The lines were then stained with tetramer at the 1:5 dilution and excess tetramer was removed with two washes. Antibody to IMHC I was then added in 20 molar excess and the samples were then assayed for tetramer staining level at time points up to four hours. Tetramer dissociates from the T cell according to the off-rate of the TCR/MHC/peptide complex and will then be bound up by the excess antibody to MHC 1. The tetramer signal decreases over time according to the off-rate. These values were plotted and the off-rate was determined as the average of three independent experiments for each T cell line ( Table 1) . The low off-rates of the FVB/N and neu-N + chemotherapy lines compared to the neu-N line provide additional evidence that in the neu-N mice high avidity T cells to self antigen exist and be activated to the self antigen. Table 1 . kof for R.NEU420429-specific T Cell Lines As the possibility exists that the results seen with the T cell lines are simply an artifact of long term culture, we next sought to confirm the data obtained from the T cell lines with experiments looking at the T cell response in the neu-N mice after only one in vitro peptide stimulation. neu-N mice were given a NT tumor challenge followed by vaccine + chemotherapy as described above. The spleens from neu-N mice that remained tumor free (6 of 42 mice), 3 tumor bearing neu-N mice, and 2 vaccinated FVB/N mice were harvested and stimulated for 7 days with RNEU 4 20-4 2 9 . On day seven, CD8+ T cells were enriched from the in vitro culture and stained for CD8, CD62L, and with increasing dilutions of tetramer. Cells were fixed and analyzed by flow cytometry. Events were gated on CD8÷, CD62LIo cells and tetramer staining intensity was compared between mice. Figure 7 shows the plots from three representative mice. Despite mouse to mouse variability, when comparing CD8÷ T cells from tumor free neu-N mice given chemotherapy and FVB/N mice, both contained high avidity RNEU 420 . 429 -specific T cells. Our data from the neu-N mice suggest a model of tolerance where a spectrum of low avidity to high avidity T cells specific to self antigens (e.g. tumor antigens) exist in the periphery, yet if vaccine alone is given only the low avidity T cells are activated. However, if vaccine is combined with immunomodulatory treatments (e.g. the chemotherapy regimen we have described) the high avidity T cells can be activated and provide a potent antitumor effect. This represents a major paradigm shift in trying to improve the efficacy of tumor vaccines. As opposed to attempts to make low avidity T cells more active, understanding the mechanisms of tolerance that prevent the activation of the high avidity tumor-reactive T cells will yield even more effective vaccines. We have focused on adoptive transfer experiments both to track the fate of RNEU 420 . 429 -specific T cells in the neu-N mice and to understand the mechanisms of tolerance that prevent the high avidity T cells from being activated.
Adoptive transfer ofT cells from FVB/N and neu-N mice to evaluate their ability to cure preestablished mammary tumors
Having established the relative avidity for RNEU 42 0-4 29 of the three T cell lines from FVBIN, neu-N (referred to as low avidity neu-N), and neu-N + chemotherapy (referred to as high avidity neu-N), we performed adoptive transfer experiments to determine their effectiveness against neu expressing tumors in vivo. An influenza hemaglutinin-specific T cell line was used as a negative control (HA T cell line). The T cells were cultured and lx10 7 cells were transferred into mice that had been challenged with tumor three days previously. Mice were monitored twice weekly for tumor growth. The mice were given twice daily injections until the completion of the experiment of interleukin 2 (IL-2). Four groups of mice were studied: 1. FVB/N (Figure 8a that the differences of the in vitro to in vivo effect are due to the fact that they are T cell lines that have been grown in long-term culture. Differences in growth properties, sensitivity to growth factors, or other factors caused by culture could explain the differences. We are continuing tõ d~411 study the differences in these T cell lines by microarray analysis in the hopes of being able to better explain the differences in activity. Thus, as other confounding variables seem to be at play in the adoptive transfer experiments using the T cell lines, we have shifted the focus of our in vivo studies to using CD8+ T cells directly from vaccinated mice that have not been cultured.
Tracking and functionality of adoptively transferred congenic T cells
We had initially hoped to be able to track transferred T cells using the H2-DqRNEU420.429 dimer or tetramer. This, however, proved to not be technically feasible. The dimer has very poor sensitivity and the tetramer is also not sensitive enough to track small populations without needing an in vitro peptide stimulation first. We also used Green Fluorescent Protein transduced T cell lines to track the T cells following transfer. Although the sensitivity was good enough to detect very few cells (data not shown), they could only be used for short term experiments as GFP is immunogenic and the mouse would mount an immune response against the transferred cells. The GFP T cells are also T cell lines and the problems discussed above with in vivo experiments would persist. A marker used by many models is Thyl (CD90). It is a membrane protein expressed at high levels on all T cells and two alleles exist (Thy 1.1 and Thyl .2) that differ by only one amino acid. High quality antibodies are available that can distinguish between the two alleles. FVB/N mice express Thy 1.1 so we performed backcrosses (10 generations) with Balb/c mice (expressing Thy1.2) to breed the Thyl.2 marker onto the FVB/N background. We can now use the FVB/N Thy 1.2 mice as a source of T cells that can be easily tracked and analyzed after transfer into FVB/N or neu-N mice.
The first experiment was to determine the fate of high avidity T cells from FVB/N mice in neu-N mice. FVB/N Thyl.2 mice were vaccinated, generating high avidity RNEU 420 . 429 specific T cells. Two weeks after vaccine, CD8+. T cells were purified from FVB/N Thyl.2 mice and 4x1 06 CD8+ T cells were transferred into FVB/N or neu-N mice that had been vaccinated earlier in the day. Two weeks after transfer, spleens were harvested and the activity of CD8÷ T cells to RNEU 4 2 0-4 2 9 was assayed by intracellular cytokine staining for interferon gamma (IFNy). Cells were stained for Thyl.2 (Thy1.2÷ cells = transferred cells, Thyl.27 cells = host cells), CD8, and IFN-y. Figure 9 shows representative results from FVB/N mice ( Figure 9a ) and neu-N mice (Figure 9b ) given vaccine and transfer of Thy 1.2 T cells. The effector RNEU 420 _ 429 -specific Thy1.2 T cells proliferated and produced IFN-y after transfer into the FVB/N host. However, the same T cells transferred into the neu-N mice were deleted, suppressed, or inactivated, as no IFN-y-producing Thy l.2+ T cells were observed. This finding suggests that mechanisms exist in the neu-N mice that do not simply prevent the activation of high avidity RNEU 4204 29 -specific T cells but can also inhibit the activity of previously activated T cells. We are currently investigating the cell type or factor that prevents the activation of these cells in the neu-N mice that is not present in the FVB/N mice. W. Iv12
Characterizing cells that prevent the activation of high avidity RNEU 42 o 4 29 -specific T cells
As we have shown that high avidity T cells to the neu self antigen can exist in neu-N mice, why these T cells are not activated by vaccine alone, but can be activated by vaccine + chemotherapy remains one of the most important questions. One hypothesis is that regulatory T cells (Tregs) , which have been shown to play an important role in preventing autoimmunity (9) , inhibit the activation of the high avidity T cells. A subset of CD4+ T cells that express CD25 have been shown to act as Treg in several models (10) . We hypothesized that this T cell subset might be suppressing the activation of the high avidity T cells and preventing effective antitumor immunity.
To test this hypothesis, neu-N mice were given vaccine + chemotherapy followed by tumor challenge two weeks after vaccine. One day prior to tumor challenge, groups of the neu-N mice received adoptively transferred T cell subsets from neu-N mice that received tumor and vaccine alone. If chemotherapy deleted or inhibited Tregs, then the adoptive transfer could restore the Trgs and inhibit the antitumor response. If the T cell subset adoptively transferred did not contain Tregs, then tumor free mice would still be observed. Figure 10 shows the results of transferring CD8+ T cells (Figure 10a ), CD4+CD25-T cells (Figure 10b) , or CD4+CD25+ T cells (Figure 10c) . Only transferring the CD4+CD25+ subset resulted in suppressing the antitumor immune response. As CD4+CD25+ T cells in neu-N mice are able to inhibit the antitumor response in neu-N mice given vaccine + chemotherpay, we wanted to see if they could inhibit the immune response in FVB/N mice where no other mechanisms of tolerance to neu should be present. neu-N mice were given tumor challenge followed by vaccine. Two weeks later the CD4+CD25+ T cells were purified and 5x10 5 Tregs were transferred into the FVB/N mice which were then vaccinated. Two weeks later the CD8+ T cell response to RNEU 4204 29 was determined in the FVB/N mice given transferred cells. As seen in Figure 11 , the mice given CD4÷CD25+ T cells from neu-N mice had significantly fewer (p=0.0 16) RNEU 42 0. 429 -specific T cells as determined by intracellular staining for IFN-'y. Although Treg transfer decreased the immune response in FVB/N mice, Tregs did not completely inhibit the immune response to RNEU 420 -429 . As no response to RNEU 420 -429 is seen in neu-N mice given vaccine alone, this indicates that although Tregs must be playing a role in neu-N mice, other factors are also at play that prevent an effective antitumor immune response. in many cases mechanisms of peripheral T cell tolerance to specific tumor antigens may be at work. A major goal of cancer research is to develop therapies that will reverse the tolerant state and allow T cells to more effectively respond to tumor. nleu-N transgenic mice display tolerance to the endogenous neu transgene and are therefore a clinically relevant model of breast cancer. The aim of our research has been to dissect the mechanisms of CD8÷ T cell tolerance in this mouse model. Knowledge of the mechanisms of tolerance in these mice will lead to the development of more effective vaccine strategies that can overcome tolerance to the neu antigen. We identified RNEU 42 o-4 29 as the immunodominant epitope in rat neu, and that neu-N mice given vaccine alone develop low-avidity CTL specific for this peptide as compared with CTL from FVB/N mice. However, if vaccine is combined with immunomodulatory chemotherapy in neu-N mice, high avidity CTL specific for RNEU 420 -42 9 are now generated. Importantly, the CTL are not only high avidity, but they are also able to eradicate tumor in the neu-N mice. Our research has focused on why these high avidity T cells can be activated only when vaccine is combined with chemotherapy and how the immune system prevents their activation when vaccine alone is given. We have shown that Tregs are an important target of the chemotherapy and that they are able to suppress the antitumor response neu-N mice. We have also shown that other, as yet undetermined, mechanisms of tolerance also play a role in the neu-N mice.
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Our work in the neu-N mouse model with combining vaccine and chemotherapy is the impetus behind a new clinical trial at our institution. Dr. Leisha Emens is currently enrolling patients on a trial combining a GM-CSF-secreting breast cancer vaccine with immunomodulatory doses of Cy and Dox. Along with clinical outcomes, blood samples are being taken to allow for the study of how the vaccine is working in humans. The findings of this trial will greatly enhance our understanding of immune tolerance to tumor antigens in humans and if chemotherapy is able to break tolerance similar to our observations in the neu-N mice.
Cancer vaccines alone have shown promise in treating cancer. However, great improvements in the efficacy of these vaccines are needed. Our work provides several critical insights into what approaches might be taken to improve the vaccines. First, we have shown that vaccine alone is not enough. Even though the vaccine is effective in a non-tolerant host, mechanisms of tolerance will prevent the activation of the most potent CTL in a tolerant host. Second, contrary to other reports, high avidity, tumor reactive T cells can persist in a tolerant host, yet they will not be activated if vaccine alone is given. And third, Tregs represent promising targets that can be manipulated to allow the high avidity, tumor reactive CTL to be activated. Our future research will continue to focus on the mechanisms of tolerance in the neu-N mice with the goal of creating vaccine approaches that will activate the high avidity CTL that are most effective at eradicating tumor. (36-38) . Knowledge of the MHC-I tion (20 gsg/l X 10" cells) to create the T2D9 cell line. T2DY cells were epitopes in neu will allow us to study the fate of T cell responses maintained at 37'C and 5% CO 2 in RPMI 1640 (Life Technologies) supplemented with 10% FBS (HyClone), 1% L-glutamine, 1% nonessential directed at these epitopes in the neu-N-transgenic tolerant mice. In amino acids, 1% sodium pyruvate, and 0.5% penicillin/streptomycin. addition, it may be possible to alter these epitopes to identify heteroclitic epitopes with improved immunogenicity in the transgenic mice. (two forelimbs and one hindlimb). Mice were sacrificed, and spleens were excised 2 wk later. Splenocyte cultures were initially stimulated every 5 dition, we show that adoptive transfer of T cells specific for this days with irradiated, IFN-y-treated NT5B7-1 cells and then every 9 days peptide is protective in vivo. Furthermore, immunization with a hetby the addition of irradiated 3T3neuB7-1 cells as stimulators and FVB/Neroclitic version of this peptide is also protective against challenge derived splenocytes as feeders. Clones were developed from this line by with mammary tumors expressing the naturally processed epitope.
neu-specific T cell lines and clones and hemagglutinin
limiting dilution. Other CD8+ T cell lines were produced from the splenocytes of mice vaccinated with a neu-expressing recombinant vaccinia or
Materials and Methods
neu plasmid DNA as described previously (24). A T cell line specific for the irrelevant Ag HA was derived from mice vaccinated with HA recomPeptides andprimers binant vaccinia virus as described previously (44) . T cells were maintained A panel of 135 peptides from fragment 4 (see Fig. 2 ) used in the initial at 37*C and 5% CO 2 in CTL medium (RPMI 1640 supplemented with 10% screening were synthesized by Chiron (Emeryville, CA). All other peptides FBS, 1% L-glutamine, 0.1% 2-ME (Sigma-Aldrich), and 0.5% penicillin/ (>95% purity) were from the Johns Hopkins Biosynthesis and Sequence streptomycin) supplemented with 10 cetus U/mI murine IL-2 (supernatant Facility (Department of Biochemistry, Johns Hopkins School of Medicine, from B16 IL-2 line (45)). Baltimore, MD). The PCR primers used to create the neu fragments (see Chromium release assays Nine overlapping fragments of the neu eDNA were created using specific GACATGAAGTTGCGGCTCCCTGAGCTGACACTGGGCCTGGAG primers and PCR amplification (Fig. IA) and then ligated into pcDNA3.1. and 3'-CCCCGGTACCCTATACAGGTACATCCAGGCCTAG. Each
The fragment constructs were then transfected into NIH 3T3 cells using fragment was ligated into the pcDNA3.1 mammalian transfection vector electroporation (20 1.g/l X 107 cells) or Lipofectamine (1.5 t.g/3 > 105 (Invitrogen, Carlsbad, CA) at the multicloning site.
cells; Life Technologies). Limiting dilution produced several clones of
Cell lines and medium each fragment. RT-PCR was performed using primers described above to determine which clones expressed fragment mRNA. The IT22 cell line derives from a spontaneously transformed mouse fibroblast line as described previously (39 Results E:T ratio. Plates were incubated at 37*C and 5% CO 2 for 24 h, and supemaGeneration of neu-specific CD8+ T cells from vaccinated FVB/ tants were harvested for the ELISA (Endogen, Woburn, MA). For the screening ofneu fragments, I X l0 T cells and 3 X 10' targets were plated in CTL N mice medium for 24 h and an ELISA was performed.
Three T cell lines were generated to characterize the T cell populations that result from different vaccination experiments as well Flow cytometry (FACS) as from different neu targeted vaccine approaches shown to be potent in other tumor models (48) . A T cell line was therefore Cells were stained by washing them two times in FACS buffer (I X HBSS generated from mice vaccinated with the 3T3neuGM whole cell (pH 7.4), 2% FBS, 1% HEPES (Life Technologies), and 0.1% NaN 3 (Sigvaccine, and 11 neu-specific T cell clones were derived from this ma-Aldrich)) and incubating with Ab for 20 min at 4°C. Staining of TCR line. In addition, lines were created from mice vaccinated with the V134, VP314, and V1317 was done using supematants from hybridomas KT4-10, 14-2, and KJ23, respectively (47) . Abs to V32, -6, and -7, and vaccinia vector expressing the entire neu protein and from mice vacfluorescence-conjugated secondary Abs were purchased from BD Pharcinated with neu plasmid DNA. All lines and clones were shown to Mingen (La Jolla, CA). Ab to CD8 was purified from the 2.43 hybridoma lyse the full-length neu protein in a S 1 Cr release assay using 3T3neu (ATCC HB-27). MHC staining was done using supernatant collected from vs 3T3 wild-type targets (not shown). Analysis of the VP usage of hybridomas 30-5-7S, 113, and 28-14-8S, which are specific for H-2Dq these T cell lines and clones suggests that the neu CD8+ T cell re-(42). The secondary Ab for all three Abs was FITC-conjugated goat antimouse IgG (BD PharMingen).
sponse is oligoclonal. Specifically, TCRs utilizing six VP regions (TCR V02, -4, -6, -7, -14, and -17) were identified (data not shown). 
Intracellular cytokine staining (ICS)
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T transfected with these constructs and used as targets in GM-CSF Table I , all vaccinated FVB/N mice developed CD8+ T cells that release assays to identify which fragment contained the peptide(s)
were specific for both full-length neu and for RNEU 42 o_ 4 29 . This recognized by the clones. ng/mL peptide ng/mL peptide FVB/N mice. The same analysis was done on the spleens of 10 compared with mice receiving a control T cell line specific for the individual neu-N mice given the same vaccine. As shown in Table  irrelevant Ag HA (p < 0.0008). This experiment was repeated I, the tolerized neu-N mice do not demonstrate appreciable T cell using several RNEU 420 o 4 29 specific T cell clones and lines with activity for the immunodominant epitope. similar results.
H-2Dq is the restriction element for RNEU 4 2 0 o 4 2 9
Initial CTL blocking studies using an Ab specific for H-2Dq and 125 -Lq (30-5-7S) indicated that lysis of neu was restricted to one of these two molecules. MHC restriction was further determined by pulsing RNEU 4 (8, (55) (56) (57) . In contrast, neu-specific T cells substituting alanine at each of the 10 positions. This type of apisolated from patients with neu-expressing breast and ovarian proach has been successful in identifying heteroclitic T cell pepcancer typically recognize multiple epitopes in both the extraceltides in both rodent and human settings (6, (49) (50) (51) (52) (53) (54) . In the majority lular and intracellular domains of the protein (58-63). Therefore, of cases, substitutions did not enhance recognition. However, our data suggest that the FVB/N nontolerized mice recognize neu when alanine was substituted for glutamate at position 2, this pepas a foreign Ag. tide (designated RNEU 420 _ 42 9 A2) demonstrated markedly im-FVB/N mice were protected against inoculation with a neu-exproved recognition by the T cell clone FVB/N VP34A in a lysis pressing in vitro tumor line (derived from naturally arising mamassay as compared with wild-type peptide (Fig. 3) . Interestingly, mary tumors in neu-N mice) when T cells specific for this epitope the heteroclitic peptide was found to have a lower binding affinity were adoptively transferred. This indicates that RNEU 42 0_ 429 is than the wild-type RNEU 42 o 0 429 peptide in a T2Dq MHC stabilithe immunodominant MHC-I epitope in rat neu that serves as the zation assay (data not shown), suggesting that its improved stimnaturally expressed tumor rejection target on spontaneously arising ulatory capacity was instead due to the enhanced stability of the neu-expressing tumors. It is interesting to note that RNEU 420 o 429 TCR/MHC/peptide complex.
differs from the corresponding murine amino acid sequence by 3 aa To determine whether this heteroclitic peptide can immunize (64). Furthermore, RNEU 420 _ 429 specific T cells do not recognize mice against mammary tumor expressing the natural RNEU 420 o 429 the murine peptide in a 51 Cr release lysis assay (data not shown). epitope, both wild-type RNEU 420 1 429 and the heteroclitic variant This probably explains its high degree of immunogenicity in the RNEU 42 o_ 42 9 A2 were used to vaccinate mice. Dendritic cells de-FVB/N mice. rived from FVB/N mice were pulsed in vitro with either of these Vaccination with the RNEU 420 _ 429 peptide pulsed onto denpeptides (or with an irrelevant peptide) and then injected s.c. into dritic cells did not demonstrate antitumor immunity. This is not FVB/N and neu-N mice followed by a s.c. NT2 tumor challenge. surprising because vaccinating mice or patients with solely As shown in Fig. 5 , mice immunized with dendritic cells pulsed MHC-I tumor epitopes has produced only modest results in most with the wild-type peptide developed tumor at about the same rate as mice immunized with an irrelevant peptide (p < 0.15 for studies. For some Ags, altering the wild-type MHC-I epitope so FVB/N mice; p < 0.39 for neu-N mice). However, FVB/N mice that it binds more strongly to MHC and/or demonstrates greater immunized with the heteroclitic peptide showed a lag in tumor recognition in vitro by Ag-specific T cells improves the immunigrowth as compared with FVB/N mice immunized with the irrelzation potential and the clinical outcome (54, (65) (66) (67) . In this study, evant peptide (p < 0.012). Although not statistically significant, we show that vaccinating FVB/N mice with dendritic cells pulsed neu-N mice demonstrated a promising trend toward protection with a heteroclitic variant of the wild-type epitope also induces when vaccinated with the heteroclitic peptide (p < 0.21).
improved protection against tumors that express the natural RNEU 42 o_ 42 9 epitope as compared with immunization with the Discussion RNEU 42 o_ 429 epitope itself. neu-N mice show a promising trend We have identified a MHC-I epitope in rat HER-2/neu, toward protection when vaccinated with the heteroclitic peptide RNEU 42 o 0 429 , which is the dominant target of the CD8+ T cell but not to the degree seen in FVB/N mice. This may reflect the response in FVB/N mice. This peptide, which is contained in the neu-specific tolerance seen in neu-N mice. In any case, this extracellular region of neu, is recognized by all neu-specific CD8+ regimen proved to be far less efficacious for either strain of mice T cell lines and clones derived from vaccinated FVB/N mice than our whole-cell vaccine, further supporting the concept regardless of the neu-targeted vaccine approach used for immunithat vaccines that induce both CTL and Th cell responses may zation. This was true even though vaccination induced an oligobe more effective than vaccines that only enhance the CTL clonal neu-specific T cell response as determined by the panel of response (41, 48) .
